Charles Ryan: Hello from APCCC 2019. I’m delighted to be joined by Oliver Sartor. Welcome, Oliver. An old friend of mine from many years, many conversations here and today we’re going to talk about the VISION trial, which is a really interesting new approach to advanced prostate cancer. You’re one of the co-PIs of the […]
Urologists devoted to the area of sexual dysfunctions are used to saying that what we treat represents just the tip of the iceberg of the bulk of the men affected with andrological conditions; consequently, the question arises on how to effectively tackle such problem. Several strategies have been developed over the years, among the others: […]
Phillip Koo: Hello. My name is Phillip Koo from UroToday.com and it’s a pleasure to be with you here today to present the final lecture in the SNMMI lecture series on prostate cancer imaging and therapies. Today we have the distinct pleasure of having with us Dr. Hossein Jadvar who’s Associate Professor of Radiology and […]
Jaime Landman: Hi, this is Jaime Landman from the University of California Irvine, and it’s Kidney Cancer Today. I’m here with my partner, friend, and cohost, Monty Pal. Monty Pal: Thanks, Jaime, how are you? Monty Pal here from City of Hope. I’m a medical oncologist, and I am just delighted to have Shaan Dudani […]
Molecular changes occurring during invasion and clinical progression of cancer are difficult to study longitudinally in patient derived material. A unique feature of urothelial bladder cancer (UBC) is that patients frequently develop multiple non muscle-invasive tumors, some of which may eventually progress to invade the muscle of the bladder wall. Here, we use a cohort […]
To apply non-muscle invasive bladder cancer (NMIBC) AUA/SUO guidelines for risk-stratification and analyze predictors of recurrence and progression. Retrospective review of 398 patients with NMIBC treated between 2001 and 2017. Descriptive statistics were used to compare AUA/SUO risk-groups. Predictors of recurrence and progression were determined by multivariable regression. Kaplan Meier analysis, Cox proportional hazards regression […]
Topical therapy of nonmuscle-invasive bladder cancer (NMIBC) is based on immunotherapy with Bacillus Calmette-Guerin and chemotherapy administered by passive instillation, but an active drug administration achieves a better concentration of the drugs in the bladder. This study aimed to investigate the effectiveness of electromotive drug administration (EMDA) of mitomycin C (EMDA/MMC) in intermediate- and high-risk […]
The International Metastatic Renal Cell Carcinoma Database Consortium(IMDC)classification is often used to predict the prognosis of patients treated with molecularly targeted agents. In this review, the authors describe the prognostic value of the neutrophil-lymphocyte ratio and C-reactive protein for Japanese patients with renal cell carcinoma. Both markers may help identify which patients are likely to […]
Brain metastases (BM) are frequently observed in advanced renal-cell carcinoma (RCC). Historically these individuals have been excluded from clinical trials, but recently, with better local control, many can receive aggressive therapy after treatment. We evaluate our single-institution experience over various treatment eras. Patients undergoing evaluation for RCC BM from 2001 to 2018 were identified from […]
Renal cell carcinomas (RCC) harboring a TFE3 gene fusion (TfRCC) represent an aggressive subset of kidney tumors. Key signaling pathways of TfRCC are unknown and preclinical in vivo data are lacking. We investigated Akt/mTOR pathway activation and the preclinical efficacy of dual mTORC1/2 versus selective mTORC1 inhibition in TfRCC. Levels of phosphorylated Akt/mTOR pathway proteins […]
